Skip to main content
. Author manuscript; available in PMC: 2012 Dec 19.
Published in final edited form as: Nat Clin Pract Oncol. 2008 Nov 18;6(1):53–58. doi: 10.1038/ncponc1278

Table 1.

[18F]FHBG Activity Ratios of Tumors Over Other Tissues

RATIOS Patient with resected side tumor
and intact center tumor, infused
with CTLs (n=1)		 Patient with intact side and
center tumor without CTL
infusions (n=1)* 		Patients with resected
side tumors, without CTL
infusions (n=3)**
Side Tumor/ Brain
BKGD		 4.82 1.54 1.82
Side Tumor/
Meninges		 1.75 0.44 0.86
Side Tumor/ Heart 0.83 0.57 0.38
Side Tumor/ Liver 0.14 0.08 0.08
Center Tumor/
Brain BKGD		 4.33 1.55
Center Tumor/
Meninges		 1.57 0.44
Center Tumor/
Heart		 0.74 0.57
Center Tumor/
Liver		 0.13 0.08
*

He was a control patient with two glioblastoma tumors that had not be surgically removed. This patient was scanned after receiving 7 mCi of [18F]FHBG.

**

Three control patients with surgically removed glioblastoma tumors, each were scanned with PET two hours after 4.2 mCi, 1.9 mCi and 5.6 mCi of [18F]FHBG injection.